![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AZ Lands Orphan Drug Designation for Neuromyelitis Optica Drug
AZ Lands Orphan Drug Designation for Neuromyelitis Optica Drug
AstraZeneca’s MedImmune unit has secured orphan drug status for MEDI-551, for treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders.
Patients with NMO and NMOSD produce antibodies that target a protein called aquaporin-4. MEDI-551 pinpoints and eliminates these antibodies, the company says.
NMO affects about five in 100,000 people, and there is currently no cure.
Upcoming Events
-
21Oct